Entrada Therapeutics, Inc. - Common Stock (TRDA)
10.50
-0.27 (-2.51%)
Entrada Therapeutics Inc is a biotechnology company focused on advancing a new class of therapeutics designed to treat a range of severe diseases
The company utilizes its proprietary protein cargo platform to develop treatments that enhance the delivery of therapeutic proteins directly into cells, aiming to address unmet medical needs in various fields, including rare and complex diseases. Entrada prioritizes innovation in drug delivery systems, striving to improve patient outcomes through targeted and efficient therapies that can potentially transform the treatment landscape for conditions where traditional methods fall short.

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne muscular dystrophy patients.
Via Benzinga · February 24, 2025

Via Benzinga · November 6, 2024

TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024

TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024

Via Benzinga · April 11, 2024

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Via Benzinga · April 11, 2024

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via Benzinga · March 22, 2024

Via Benzinga · November 27, 2023

Via Benzinga · November 23, 2023

Entrada Therapeutics Inc (NASDAQTRDA) shares are trading lower after the company announced updates on ENTR-601-44 in
Via Benzinga · November 22, 2023

Via Benzinga · November 22, 2023

Via Benzinga · April 3, 2023

Via Benzinga · March 9, 2023

Via Benzinga · February 16, 2023

Gainers Sera Prognostics, Inc. (NASDAQSERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL.
Via Benzinga · February 15, 2023

Via Benzinga · February 15, 2023

Via Benzinga · February 14, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday.
Via Benzinga · December 20, 2022
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · December 20, 2022

U.S. stocks traded mixed midway through trading, with the S&P 500 and the Nasdaq Composite moving lower on Tuesday.
Via Benzinga · December 20, 2022

Gainers IceCure Medical Ltd (NASDAQICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
Via Benzinga · December 20, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via Benzinga · December 20, 2022

Gainers IceCure Medical Ltd (NASDAQICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who cannot be offered kidney-preserving surgery.
Via Benzinga · December 20, 2022